Batch manufacture of high titer/titre GMP (U.S.A.) compliant lentiviral vector for FDA approval
University Of Edinburgh · Awarded
- Buyer
- University Of Edinburgh
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Manufacturing
- Reference
- FaT-ocds-h6vhtk-0568ca
- Published
- 2025-12-08
- Deadline
- 2026-04-18
Tender summary
We are planning a phase I/II clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy will use autologous CD34+ haematopoietic stem progenitor cells (HSPCs) which are modified ex vivo with LVV to express supraphysiologic levels of a secreted enzyme. In order to progress this therapy, we require a high titre LVV produced to good manufacturing practice (GMP) standard. The supplier must have extensive previous experience manufacturing LVVs to this specification which have achieved regulatory approval for phase I/II clinical trials, ideally for use…
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access